* Spyre Therapeutics Inc SYRE.OQ reported a quarterly
adjusted
loss of 86 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of $-41.50. The mean expectation of eight analysts
for the quarter was for a loss of 95 cents per share. Wall
Street expected results to range from $-1.21 to -52 cents per
share.
* Reported revenue was zero; analysts expected $4.00
million.
* Spyre Therapeutics Inc's reported EPS for the quarter was
a loss
of 86 cents.
* The company reported a quarterly loss of $38.84 million.
* Spyre Therapeutics Inc shares had risen by 7.4% this
quarter and
gained 17.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 7.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Spyre
Therapeutics Inc is $50.00
This summary was machine generated from LSEG data August 9 at
01:51 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.95 -0.86 Beat
Mar. 31 2024 -1.17 -1.20 Missed
Dec. 31 2023 -0.78 -4.05 Missed
Sep. 30 2023 -0.84 -9.34 Missed